INTRODUCTION
============

Initiation of DNA replication requires prior assembly of the prereplicative complex (pre-RC) by Cdc6- and Cdt1-dependent recruitment of the minichromosome maintenance complex (Mcm2--7) to the origin-bound origin recognition complex (Orc1-6) ([@B2]). Pre-RC assembly licenses the origin to further recruit the Dbf4-kinase/Cdc7 complex to form a bidirectional replication fork ([@B2]). DNA synthesis then occurs through the activity of S-phase/mitotic cyclin-Cdk complexes ([@B51]; [@B55]). In *Saccharomyces cerevisiae*, this includes six B-type cyclins (Clb1--6) and one Cdk1 (Cdc28p) ([@B38]).

Cells ensure that DNA replication occurs only once per cell cycle in order to maintain genome integrity. To achieve this, the pre-RC is rapidly disassembled after Cdk1-dependent phosphorylation, and reassembly is inhibited until the following cell cycle. The inhibition of pre-RC assembly is dependent on B-type cyclins ([@B9]; [@B21]) and involves multiple overlapping mechanisms. Mcm2--7 is excluded from the nucleus after phosphorylation by the cyclin-Cdk complex ([@B27]; [@B40]). Orc2 and Orc6 are phosphorylated to inhibit pre-RC loading ([@B41]). To further prevent pre-RC assembly, Clb2 binds to the phosphorylated N-terminal domain of Cdc6 ([@B35]), and Clb5p binds to the Arg-X-Leu (RXL) domain in Orc6 to sterically inhibit Cdt1/Mcm2--7 loading ([@B7]; [@B54]). In addition, Cdc6p levels are tightly regulated during the cell cycle. Cdc6 is transcribed in late mitosis and G1 and accumulates throughout G1; then its levels rapidly drop after passage through START ([@B44]; [@B57]). Cdc6 is also regulated through its localization ([@B20]).

Multiple mutations affect rereplication control, including mutation of Orc2 and Orc6 phosphorylation sites (*ORC2-ps* and *ORC6-ps*) ([@B41]), forced nuclear localization of Mcm2--7 (*MCM7-NLS*) ([@B40]), and stabilization through N-terminal truncation of Cdc6p (*CDC6ΔNT*) ([@B12]). Combining these mutations is lethal and induces rereplication ([@B41]; [@B54]; [@B3]). In addition, each of these individual mutations strongly synergizes with *ORC6* mutation at the RXL domain (*ORC6-rxl*) ([@B54]). For instance, an *ORC6-rxl CDC6ΔNT* double mutant causes slow growth and increases the frequency of rereplication, with the functional outcome of causing DNA damage and activating the DNA damage checkpoint ([@B3]; [@B21]).

We previously found that the *ORC6-rxl* mutation is synthetically lethal with the deletion of the *MCK1* gene, a yeast homologue of glycogen synthase kinase 3 (GSK-3) ([@B3]; [@B22]). [M]{.ul}eiosis and [c]{.ul}entromere regulatory [k]{.ul}inase (Mck1) is a serine/threonine kinase whose catalytic activity requires autophosphorylation on tyrosine residues ([@B29]; [@B6]; [@B47]). Mck1p was first found as a dosage suppressor of a centromere mutation that causes chromosomal missegregation ([@B50]) and as an early regulator of genes required for meiosis and sporulation ([@B39]). In addition, it is involved in the stress response by promoting the binding of transcription factors to the promoters of stress-responsive genes ([@B19]). Accordingly, *mck1-*deletion cells are hot and cold sensitive and sensitive to the microtubule-destabilizing drug benomyl ([@B50]; [@B1]). Mck1 has a function in protein degradation; during heat stress, it promotes Rog1 degradation through the ubiquitin-ligase Rsp5 ([@B1]). Mck1 also has a role in cell cycle regulation. It is a downstream regulator of calcineurin signaling that promotes ubiquitin-mediated Hsl1 degradation ([@B36]) and Rcn1 degradation ([@B25]). Mck1 also phosphorylates the sister cohesion protein Eco1, after Dbf4-kinase/Cdc7 and Cdk1-dependent priming phosphorylation, for ubiquitin-mediated degradation ([@B33]).

There are eight CDK consensus sites in the N- and C-termini of Cdc6 that target Cdc6 for ubiquitin-mediated proteolysis ([@B12], [@B13]; [@B15]; [@B43]). In mitosis, Cdc6p is degraded through the SCF^Cdc4^ ubiquitin ligase, which is dependent on Cdc6 T368 and S372 ([@B12], [@B13]). Previously, we elucidated a novel function of Mck1 for DNA rereplication inhibition ([@B22]). We found that Mck1 promotes Cdc6 degradation in a SCF^Cdc4^-dependent manner through the C-terminus. The C-terminal residues ^368^TPTTSP^372^ in Cdc6 contain a GSK-3 consensus site in the form S/TxxxS/Tp. Theoretically, GSK-3 kinase phosphorylates the first S/T after the priming phosphorylation of the S/T residue at the fourth position by another kinase ([@B16]). T368 and S372, which are important for Cdc6 degradation during mitosis, have been studied as putative Cdk1 phosphorylation sites ([@B13]).

In this article, we provide evidence in vitro and in vivo that Mck1, but not Cdk1, phosphorylates T368 only after priming phosphorylation of S372 by Clb2-Cdk1 to promote Cdc6 degradation during mitosis. The Cdc6 phosphodegron created by Cdk1 and Mck1 is crucial for Cdc4 binding to promote Cdc6 degradation. We also show that GSK3-dependent Cdc6 degradation is augmented after DNA damage stress in order to maintain genome integrity.

RESULTS
=======

GSK-3 consensus site at T368-S372 in Cdc6 is responsible for Cdc6 degradation
-----------------------------------------------------------------------------

The GSK-3 consensus motif contains S/T-x-x-x-S/T. There are two GSK-3 consensus sites in Cdc6, one at each terminus ([Figure 1A](#F1){ref-type="fig"}). The TPTTS GSK-3 consensus site (T368 to S372) in Cdc6 is overlapped with two CDK sites at TP (368 and 369) and SP (372 and 373) ([Figure 1A](#F1){ref-type="fig"}). We mutated each amino acid from Thr, Ser, or Pro in the GSK-3 consensus site to Ala and examined the stability of Cdc6p. Wild-type Cdc6p was degraded after expression was shut off during mitosis ([Figure 1B](#F1){ref-type="fig"}; [@B12], [@B13]; [@B43]). Cdc6-T368A, P369A, S372A, and P373A single mutants or T368A-S372A double-mutant proteins were stabilized, as was Cdc6p in *mck1-*deletion cells, indicating that the GSK consensus sequence from T368 to S372 is crucial for Cdc6 degradation ([Figure 1B](#F1){ref-type="fig"}; [@B43]). Cdc6 stabilization by P369A or P373A mutation indicates that T368 or S372 might be potential Cdk1 phosphorylation sites. A single mutation in Cdc6 at the N-terminus, T39A or S43A, did not alter Cdc6p stability during mitosis ([Figure 1B](#F1){ref-type="fig"}). However, we observed high Cdc6p protein levels at time zero when the two mutations at the GSK-3 consensus sites T39A and T368A were combined ([Figure 1B](#F1){ref-type="fig"}). Consistent with Cdc6 protein stability in *CDC6-T39A, T368A* double mutations ([Figure 1B](#F1){ref-type="fig"}), we found that *GAL-CDC6-T39A, T368A* cells showed elongated bud and mitotic arrest ([Figure 1D](#F1){ref-type="fig"} and Supplemental Figure S1). We also observed more stabilized Cdc6p in *CDC6-T368A* or *CDC6-T39A, T368A* cells than in *Δmck1* cells ([Figure 1B](#F1){ref-type="fig"}). This indicates that Cdc6-T368 site is phosphorylated by multiple kinases.

![Analysis of GSK-3 consensus sites in Cdc6. (A) Cdc6 contains two GSK-3 consensus sites, which overlap with two CDK consensus sites. (B) *GAL-CDC6-HA* strains with various mutations (T368A, P369A, S372A, P373A, T39A, S43A, T39A-T368A, and T368A-S372A) were expressed with galactose-containing medium for 2 h and then blocked with nocodazole for 2 h. Cdc6 expression was then suppressed by adding glucose. Protein extracts were collected every 5 min and subjected to Western blot analysis to observe Cdc6-HA. Pgk1 was used as a loading control. *GAL-CDC6-HA* in *mck1*-deletion cells was examined using the same method. Western blotting images for WT, *Δmck1*, *CDC6-T39A*, *CDC6-T368A*, and *CDC6-T39A,T368A* were quantified. Percentage of Cdc6 protein remaining relative to time zero is shown. Results are the average of three independent experiment, and error bars indicate SD. \**p* \< 0.05. (C) Strains with the indicated genotypes were serially diluted 10-fold, plated on yeast extract/peptone/dextrose or yeast extract/peptone/galactose plates, and incubated at 30°C for 2 d. (D) *GAL-CDC6*, *GAL-CDC6-T368A*, or *GAL-CDC6-T39A-T368A* was grown in raffinose-containing medium first. Cdc6p was expressed with galactose for 3 h.](2609fig1){#F1}

We previously found that *mck1* deletion is synthetically lethal with an *ORC6-rxl* mutation that disrupts a control for DNA rereplication ([@B22]). Given the Cdc6p stabilization in *mck1*-deletion cells ([Figure 1B](#F1){ref-type="fig"}), we tested whether the *CDC6* GSK-3 consensus-site mutations that stabilized Cdc6p also induce enhanced synthetic lethality in the *ORC6-rxl* mutant. Viability of yeast cells that contain various *CDC6* mutations and the *ORC6-rxl* mutation were tested. The *GAL-CDC6 ORC6-rxl* mutant caused increased lethality on galactose-containing plates compared with controls ([Figure 1C](#F1){ref-type="fig"}). The lethality was exacerbated when cells contained *CDC6* mutations (T368A, P369A, S372A, and P373A single mutants or T368A and S372A double mutants) at the GSK-3 consensus sites ([Figure 1C](#F1){ref-type="fig"}, top). *ORC6-rxl GAL-CDC6-T39A, T368A* cells showed enhanced lethality compared with *ORC6-rxl GAL-CDC6-T39A* or *ORC6-rxl GAL-CDC6-T368A* ([Figure 1C](#F1){ref-type="fig"}, bottom). Next the *CDC6-T368A* mutation was integrated into the genome locus and was crossed with the *ORC6-rxl* and *ORC6-rxl,ps* mutants. The resulting double mutants, *ORC6-rxl CDC6-T368A* and *ORC6-rxl,ps CDC6-T368A*, showed slow growth (Supplemental Figure S2).

Mck1 phosphorylates Thr-368 in Cdc6 after priming by Clb2/Cdk1
--------------------------------------------------------------

To identify the Cdk1 or Mck1 phosphorylation sites on Cdc6, we performed an in vitro kinase assay using various Cdc6 synthetic peptides with Mck1p kinase or Cdk1p kinase purified from yeast. Clb2/Cdk1 phosphorylated the wild-type Cdc6 synthetic peptide containing the C-terminal GSK-3 consensus site; however, the phosphorylation was abolished when the Cdc6 peptide contained a phosphate at S372 ([Figure 2A](#F2){ref-type="fig"}, left). This indicates that Clb2/Cdk1 targets the S372 site but not the T368 site. On the other hand, Mck1 did not phosphorylate the wild-type Cdc6 peptide unless the peptide contained a phosphate at S372 ([Figure 2A](#F2){ref-type="fig"}, left). The Mck1-dependent Cdc6 phosphorylation was abolished when we used Cdc6 peptides that contained an alanine mutation at T368 ([Figure 2A](#F2){ref-type="fig"}, left). This result proved that Cdc6-T368 is phosphorylated by Mck1 in vitro. Mck1 weakly phosphorylated the Cdc6 peptide that contained the N-terminal GSK-3 consensus site at T39. However, the phosphorylation efficiency was ∼20-fold less than that at the C-terminal T368 ([Figure 2A](#F2){ref-type="fig"}, right). Clb2/Cdk1 did not phosphorylate the Cdc6 peptide that contained the Cdk1 consensus site at T39 and S43 ([Figure 2A](#F2){ref-type="fig"}, right).

![Mck1 phosphorylates the T368 site in Cdc6 after priming by Clb2-Cdk1. (A) To measure Clb2-Cdk1 and Mck1 kinase activities on Cdc6 phosphopeptides, various synthetic peptides of Cdc6 (residues 36--47 or 365--376; shown above) were incubated with purified kinases from asynchronous yeast cultures and \[γ-^32^P\]ATP. For each kinase, phosphate incorporation was normalized to a control reaction without peptides. Values for the C-terminal peptides represent the average from three independent experiments. Error bars represent SD. (B) Indicated strains were grown in raffinose-containing medium first. Cdc6 expression was induced with galactose for 2 h. Cells were blocked with nocodazole or α-factor for 2 h. Western blotting was performed using anti--phosphoT368 of Cdc6, anti-HA, anti-Pgk1, and anti-Clb2 antibodies, respectively. (C) Indicated strains were grown in raffinose-containing medium first, and then galactose was added to induce Cdc6 expression for 2 h. Cells were blocked with nocodazole for 2 h. Western blotting was performed using anti--phosphoT368 of Cdc6, anti-HA, and anti-Pgk1 antibodies, respectively (left). Band intensity for the phospho-Cdc6-T368 was quantified and normalized to the total amount of Cdc6 (right). The ratio phospho-T368/total Cdc6 in *Δclb4* was set as 1. Results are the average of three independent experiments; error bars indicate SD.](2609fig2){#F2}

Next we tested whether Mck1 kinase phosphorylates Cdc6-T368 in vivo, using a phosphospecific antibody against the T368 site. Cdc6 was phosphorylated at the T368 site in wild-type cells when the cell cycle was arrested during mitosis using nocodazole ([Figure 2B](#F2){ref-type="fig"}, left). The Cdc6-T368 phosphorylation was abolished in the Cdc6-T368A mutant as well as in *Δmck1* cells. We did not detect T368 phosphorylation when the priming site at S372 was mutated to alanine, indicating that Mck1 phosphorylates T368 only when the S372 priming site is phosphorylated ([Figure 2B](#F2){ref-type="fig"}, left). Furthermore, the T368 site was not phosphorylated in wild-type cells arrested in G1 phase with α-factor ([Figure 2B](#F2){ref-type="fig"}, right). These results support our priming model ([@B22]) that Cdc6 requires Cdk1-dependent priming at S372 in order to be phosphorylated by Mck1 at T368 during mitosis.

We next tested the cyclin dependence of Mck1-induced Cdc6 phosphorylation at T368. The phosphorylation status of Cdc6-T368 was analyzed in vivo in *GAL-CDC6, Δclb2 GAL-CDC6, Δclb4 GAL-CDC6* or *Δclb5 GAL-CDC6* cells during mitosis. Cdc6-T368 phosphorylation was dependent on the mitotic cyclin Clb2 ([Figure 2C](#F2){ref-type="fig"}), which is consistent with our in vitro kinase assay results. The phosphorylation was also dependent on the S-phase cyclin Clb5. However, the phosphorylation was still observed in *clb4*-deletion cells ([Figure 2C](#F2){ref-type="fig"}).

Cdc6 phosphorylation by Mck1 and Cdk1 creates a Cdc4 phosphodegron
------------------------------------------------------------------

We previously proposed a model in which double phosphorylation of Cdc6 by Mck1 and Cdk1 may create a phosphodegron that is recognized by Cdc4 ([@B22]). To test this, we created a *GAL-CDC6-Δ370* mutant strain lacking one amino acid between the Mck1 and Cdk1 phosphorylation sites and whose expression is controlled under the *GAL* promoter. Similar to wild-type Cdc6p, the Cdc6-Δ370 protein was still degradable after glucose addition, whereas the Cdc6-Δ370Δ371 protein, lacking two of the three amino acids of the phosphodegron, was more stable than both single mutants ([Figure 3A](#F3){ref-type="fig"}). Cdc6-T370A or Cdc6-T371A proteins were also degraded, signifying that spacing and not the specific amino acid sequence of 370 and 371 is critical for recognition, potentially by Cdc4 ([Figure 3A](#F3){ref-type="fig"}). To determine whether Cdc4 binds to Cdc6 with specific spacing between the two phosphorylations at T368 and S372, we tested the binding efficiency between Cdc4 and Cdc6 by a yeast two-hybrid assay. Consistent with the stabilization data, Cdc4 did not bind to Cdc6-Δ370Δ371 ([Figure 3B](#F3){ref-type="fig"}). However, Cdc4 recognized wild-type Cdc6 and Cdc6-Δ370 ([Figure 3B](#F3){ref-type="fig"}). Each LexA-Cdc6 fusion protein was expressed at comparative levels, and therefore the protein-binding defect between Cdc4 and Cdc6 in the Cdc6-Δ370Δ371 mutant is not due to poor protein expression levels ([Figure 3B](#F3){ref-type="fig"}, bottom). We conclude that Cdc4 binds to the Cdc6 phosphodegron at T368 and S372 when there are two or three amino acids between phosphorylations. Only one amino acid between phosphorylations (Cdc6-Δ370Δ371) causes stability because Cdc4 does not recognize it. T368M mutant was used as a negative control ([@B43]).

![Cdc6 phosphodegron for Cdc4. (A) *GAL-CDC6-HA* strains with various mutations (*Δ370Δ371*, *Δ370*, *T370A*, or *T371A*) were incubated in raffinose-containing medium and transferred to galactose-containing medium for 2 h to induce Cdc6 expression, and then cells were blocked with nocodazole. Cdc6 expression was suppressed by adding glucose. Protein samples were collected every 5 min and subjected to Western blot analysis to observe Cdc6-HA. Pgk1 was used as a loading control. Western blotting images were quantified. Results represent the average of three experiments, with error bars indicating SD. (B) Yeast two-hybrid analysis was performed to determine the binding between Cdc4p and the Cdc6p C-terminus. Full-length *CDC4* in the pACT plasmid, containing the *GAL4* activation domain (GAD), was cotransformed into L40 yeast strains along with the various *CDC6* mutants in the pBTM116 plasmid fused to LexA. Transformants were assayed for β-galactosidase activity, as visualized in blue. Proteins were extracted from each strain (1--4), and Cdc6 protein levels were examined by Western blotting.](2609fig3){#F3}

Cdc6 degradation upon DNA damage is mediated by Mck1
----------------------------------------------------

It has been shown that the DNA alkylating agent methyl methanesulfonate (MMS) triggers Cdc6 degradation in *S. cerevisiae* ([@B18]). We tested the possibility that DNA damage--induced Cdc6 degradation is dependent on Mck1 kinase. Cdc6p from the endogenous promoter was degraded after MMS treatment, as previously reported ([Figure 4A](#F4){ref-type="fig"}; [@B18]), whereas Orc6 and Mck1 protein levels remained stable ([Figure 4B](#F4){ref-type="fig"}). This suggests that MMS-induced protein degradation is specific to Cdc6p and is not indicative of an overall reduction in replication protein or general protein levels. The MMS-dependent Cdc6 degradation was suppressed in *Δmck1* cells ([Figure 4A](#F4){ref-type="fig"}), suggesting that Cdc6 degradation after DNA damage was mediated by Mck1 kinase. We also observed suppression of Cdc6 degradation in the *CDC6-T368A* mutant, in which T368A mutation was integrated at the endogenous locus ([Figure 4C](#F4){ref-type="fig"}). We conclude that DNA damage triggers Mck1-dependent Cdc6 degradation.

![DNA damage triggers Cdc6 degradation in Mck1-dependent manner. (A) *CDC6-prA* or *Δmck1 CDC6-prA* cells were incubated in yeast extract/peptone/dextrose (YEPD) medium to log phase, and then MMS was added (0.05% final). Protein extracts were made at 0-, 30-, or 60-min incubation and subjected to Western blotting to visualize endogenous Cdc6-prA. Pgk1 was used as a loading control. The same experiment was repeated three times to quantify Cdc6 protein levels. Average percentage of Cdc6p remaining is shown. Bars represent SD. (B) Protein degradation of Orc6-prA or Mck1-9MYC was examined by the same method using IgG or anti-MYC antibodies, respectively. (C) *CDC6-prA* or *CDC6-T368A-prA* cells were grown in YEPD to log phase. MMS at 0.1% concentration was added, and protein samples were collected after 0, 30, and 60 min. The protein extracts were subjected to Western blotting to visualize Cdc6-prA. The same experiment was performed three times. Cdc6 protein levels were quantified, and average percentage of Cdc6p remaining is shown. Bars represent SD.](2609fig4){#F4}

Cdc6 degradation is mediated by the SCF^Cdc4^ complex ([@B12]; [@B15]; [@B43]). We found that MMS-induced Cdc6 degradation was suppressed when Cdc4 was defective ([Figure 5A](#F5){ref-type="fig"}). Most likely, Cdc6 phosphorylations upon DNA damage are recognized by the SCF^Cdc4^ complex for subsequent Cdc6p ubiquitination. It is known that Cdc6 degradation is also mediated through Tom1 and Dia2 ([@B18]; [@B24]). We further tested whether Cdc6 degradation upon MMS treatment is mediated by the Tom1 or Dia2 ubiquitin ligases. We did not observe significant difference in Cdc6 degradation rate between wild-type, *Δdia2*, or *Δtom1* deletion cells after MMS treatment (Supplemental Figure S3).

![Cdc6 degradation upon DNA damage is mediated through the ubiquitin pathway. (A) *CDC6-prA* or *cdc4-1 CDC6-prA* cells under the endogenous promoter were grown to log phase at 26°C first and then the temperature was increased to 36°C for 1.5 h. Then MMS was added (0.1% final). Samples were collected after 0, 30, or 60 min. The same experiment was performed three times, and Cdc6 protein levels were quantified. Error bars represent SD. (B) *RAD52-YFP* or *Δmck1 RAD52-YFP* cells were grown to log phase in low-fluorescence medium. MMS was added (0.05% final) for 90 min. Rad52-YFP foci were visualized under a fluorescence microscope to assay for double-stranded DNA breaks before and after treatment with MMS. Percentage of cells containing Rad52 foci was determined in unbudded or budded cells. One hundred cells were counted for each sample. Percentage is average from three independent experiments, and error bars represent the SD. \**p* \< 0.05. (C) *GAL-CDC6* or *GAL-CDC6-T368A* cells were grown to log phase in raffinose-containing medium first, and then either glucose or galactose was added for 3 h of incubation. Finally, MMS was then added (0.05% final) for 1 h. Rad52-YFP foci formation was determined with or without MMS treatment. One hundred cells were counted for each sample. Percentage is average from three independent experiments, and error bars represent SD. (D) *cdc4-1 GAL-CDC6-HA* cells were incubated in raffinose-containing medium first. Galactose was then added for 1 h of incubation, followed by nocodazole for 1.5 h. The temperature was then raised to 36°C to inactivate Cdc4 function for 1.5 h. Finally, cells were treated with MMS (0.1% final) and sampled every 30 min. Western blotting was performed using anti-phosphoT368 of Cdc6 and anti-HA. Control experiment was performed in raffinose-containing medium, indicated as "pre." (E, F) Cells with indicated genotypes were serially diluted 10-fold on yeast extract/peptone/dextrose or yeast extract/peptone/galactose plates containing 0.002% MMS. The plates were incubated at 30°C for 2 d.](2609fig5){#F5}

Cells with stabilized Cdc6 are susceptible to DNA damage
--------------------------------------------------------

The homologous recombination protein Rad52 localizes to sites of double-stranded DNA breaks (DSBs) ([@B31]). MMS increases the frequency of DSBs in budded cells, as detected by the formation of Rad52-YFP foci ([@B30]), likely due to an increased frequency of replication fork collapse ([@B52]). To test the functional significance of Mck1-mediated Cdc6 degradation during DNA damage stress, we counted the frequency of Rad52-YFP foci in wild-type cells or *Δmck1* cells after MMS treatment. In unbudded cells during G1 phase, we did not observe a significant difference in the frequency of Rad52-YFP foci between wild-type and *Δmck1* cells after MMS treatment ([Figure 5B](#F5){ref-type="fig"}). Consistent with previous work, however, more Rad52-YFP foci were formed in wild-type budded cells, both with and without MMS treatment ([Figure 5B](#F5){ref-type="fig"}; [@B30]). In untreated *Δmck1* cells, we observed a statistically higher rate of Rad52--yellow fluorescent protein (YFP) foci formation ([Figure 5B](#F5){ref-type="fig"}). The Rad52-YFP foci frequency was increased after MMS treatment in both wild-type and *Δmck1* cells, but more strikingly in Δ*mck1* cells ([Figure 5B](#F5){ref-type="fig"}). Furthermore, cells expressing *GAL-CDC6-*T368A, which contains a mutation at the Mck1 phosphorylation site, had an increase in the frequency of Rad52-YFP foci formation after MMS treatment when grown in galactose-containing but not glucose-containing media compared with *GAL-CDC6* cells ([Figure 5C](#F5){ref-type="fig"}).

We further obtained evidence that the Cdc6-T368 site is more phosphorylated after MMS treatment ([Figure 5D](#F5){ref-type="fig"}). This result supports our conclusion that Cdc6 is degraded after phosphorylation at the T368 site through Mck1 kinase. To test whether Mck1 has a role in preventing lethality in response to DNA damage, we tested cell viability of *Δmck1* cells in MMS. The *Δmck1* cells were not sensitive to MMS, indicating that cell viability of *Δmck1* was maintained due to DNA damage checkpoint activation in the presence of MMS ([Figure 5E](#F5){ref-type="fig"}). We therefore tested whether deletion of a DNA damage checkpoint component may enhance lethality in *Δmck1* cells. Deleting both *MRE11* (a part of the MRX complex) and *MCK1* genes enhanced lethality in response to MMS ([Figure 5E](#F5){ref-type="fig"}). Furthermore, a combination of *Δmre11* and the *GAL-CDC6-T368A* mutation also enhanced the cell lethality to MMS ([Figure 5E](#F5){ref-type="fig"}), supporting the idea that DNA damage in *Δmck1* or *GAL-CDC6-T368A* cells is augmented when a DNA checkpoint component is eliminated.

We next tested whether the endogenous *CDC6-T368A* mutation behaves in the same way as *GAL-CDC6-T368A*. The *CDC6-T368A* cells did not show significant MMS sensitivity, similar to *Δmck1* ([Figure 5F](#F5){ref-type="fig"}). Furthermore, *Δmre11 CDC6-T368A* double mutant did not have a significant difference in viability in response to MMS compared with *Δmre11* ([Figure 5F](#F5){ref-type="fig"}). We created *CDC6-T39A,T368A*, in which both mutations were integrated into the endogenous locus. *CDC6-T39A,T368A* cells did not show MMS sensitivity ([Figure 5F](#F5){ref-type="fig"}). However, deleting *MRE11* in CDC6-T39A,T368A cells enhanced lethality, similar to *Δmck1 Δmre11* ([Figure 5F](#F5){ref-type="fig"}). Furthermore, there was increased Rad52 foci formation in budded cells with endogenous *CDC6-T39A,T368A* after MMS exposure (Supplemental Figure S4).

DISCUSSION
==========

The mechanism of Cdc6 protein degradation is complex. Cdk1-dependent Cdc6 phosphorylations and degradations have been extensively studied in order to understand the molecular mechanism of Cdc6 control. The Cdc6 phosphorylation sites have been studied based on the CDK consensus motif ST or TP ([@B13]; [@B43]; [@B5]; [@B20]). There are two GSK-3 consensus sites in Cdc6 ([Figure 1A](#F1){ref-type="fig"}). Both of the GSK-3 sites in Cdc6 overlap with two CDK consensus sites; the second of each CDK site, at S43 or S372, is conserved, as it contains a lysine at the fourth position, K46 and K375, respectively ([Figure 1A](#F1){ref-type="fig"}). In this study, we found that the phosphorylation site at T368 in Cdc6, which was previously studied as a CDK site, is actually a GSK-3 phosphorylation site ([Figure 2](#F2){ref-type="fig"}). GSK-3 kinase requires priming phosphorylation ([@B28]; [@B33]). Therefore we hypothesized that within the GSK-3 consensus site in Cdc6p (^368^TPTTS^372^), S372 would serve as the priming site for T368 phosphorylation by Mck1 ([@B22]). Because S372 occurs within a conserved Cdk1 site (T/SPxR/K), we predicted that Cdk1 would provide this priming phosphorylation ([@B22]). We showed that T368 is phosphorylated by Mck1 ([Figure 2A](#F2){ref-type="fig"}). The Cdc6-S372 site, followed by a basic residue at the fourth position, was efficiently phosphorylated by Clb2/Cdk to serve as the priming phosphorylation site. Mck1 also phosphorylated the Cdc6 N-terminal GSK-3 consensus site at T39, but with less efficiency ([Figure 2A](#F2){ref-type="fig"}). We also tested the possibility that Clb2/Cdk1 phosphorylates S43, the other conserved CDK site, but we determined that it did not (unpublished data). It is possible that G1 cyclins or S-phase cyclins coupled with Cdk1 may phosphorylate the S43 site. This would allow cell cycle--dependent Cdc6 degradation whose timing relies on Cdk1-priming.

The GSK-3 consensus sequence, S/T-x-x-x-S/T, contains three amino acids between the priming and phosphorylation sites. Together, they create a phosphodegron for SCF^Cdc4^-dependent ubiquitination ([@B22]; [@B33]). The GSK-3 sites at the N-terminus and C-terminus of Cdc6 coincide with a binding site for the Cdc4 E3 ubiquitin ligase ([@B43]). It was shown that the protein binding between Cdc4 and Cdc6 is abolished when there is a mutation at T368 or S372 ([@B43]). Here we show that the double phosphorylations created by Cdk1 at S372 and Mck1 at T368 serve as a phosphodegron for Cdc4 binding. The spacing of two or three, and not one, amino acids between the two phosphorylations is important for Cdc4 recognition ([Figure 3B](#F3){ref-type="fig"}). This is consistent with a previous report for Eco1p ([@B33]). Mck1 requires a priming phosphorylation. For example, Eco1 must be primed by Dbf4 and Cdk1 for cohesion function regulation ([@B33]) and Rpc53 must be primed by Kns1 in the TOR signaling pathway before Mck1 can phosphorylate either substrate ([@B28]). Possibly, Mck1 substrates are favored targets of Cdc4 ([@B36]; [@B25]; [@B22]; [@B33]; [@B14]), because the GSK-3 consensus motif and the priming model can determine precise Cdc4 specificity. These reports, together with our findings, strongly suggest that there might be more GSK-3 substrates that are targeted in a Cdc4-dependent manner.

The presence of a separate Mck1-dependent degradation mechanism of Cdc6 raised the question of why such a mechanism is needed. First, we tested whether Mck1 is regulated in a cell cycle--dependent manner. Mck1 protein was stable throughout the cell cycle, as were its localization and kinase activities (Supplemental Figure S5). Mck1 was shown to promote protein degradation in response to stress ([@B1]). We therefore reasoned that the Mck1-dependent Cdc6p degradation could be involved in the cell\'s response to stress. The Cdc6 degradation in response to MMS was dependent on Mck1 kinase ([Figure 4, A](#F4){ref-type="fig"} and [C](#F4){ref-type="fig"}). Furthermore, MMS-induced Cdc6 degradation was mediated through SCF F-box protein (Cdc4) ([Figure 5A](#F5){ref-type="fig"}). The continuous Mck1 activity throughout the cell cycle may help to phosphorylate and degrade Cdc6p when cells are exposed to DNA damage agent.

We also tested whether hydroxyurea (HU) or benomyl promotes Cdc6 degradation, since *Δmck1*-deletion cells are sensitive to these reagents ([@B50]). However, Cdc6 was stable after HU or benomyl treatment (Supplemental Figure S6). These results indicate that Mck1-dependent Cdc6 degradation is triggered by specific DNA damage through alkylating agents. It has been reported that Sld3 is phosphorylated and inhibits late origin firing when cells are treated with MMS ([@B32]; [@B56]). The inhibition of late origin firing is dependent on Rad53 ([@B32]; [@B56]). Mck1-dependent Cdc6 degradation may serve as an additional mechanism to block origin firing, and it would be of interest to know whether the Mck1-dependent mechanism inhibits early and/or late origin firing. It remains to be investigated whether Mck1 is activated upon DNA damage directly. We observed that Cdc6 is more stabilized in *CDC6-T368A* than in *Δmck1* ([Figure 1B](#F1){ref-type="fig"}). This result raised the possibility that Cdc6p may be phosphorylated through another kinase, such as Rad53 or Mec1.

Cells undergoing S phase are more prone to DNA damage by MMS ([@B30]). We also observed that *Δmck1* cells accumulate more DNA damage in budded cells, which includes S-phase cells, than in wild-type cells ([Figure 5C](#F5){ref-type="fig"}). We conclude that DNA replication has to be controlled and inhibited in early S phase by inhibiting Cdc6p so that cells do not proceed through S phase when cells are exposed to DNA damage agents. Continuous initiation of DNA replication during S phase under DNA damage stress will lead to accumulation of DNA damage and lethality.

It will be also interesting to identify novel Mck1 substrates. We searched for proteins that contain a GSK-3 consensus motif similar to that in Cdc6, S/T-P-X-X-S/T-P-X-R/K. Using the MOTIF search database ([www.genome.jp/tools/motif/MOTIF2.html](http://www.genome.jp/tools/motif/MOTIF2.html)), we identified 17 candidate proteins that contain a similar GSK-3 consensus sequence, including three DNA replication proteins, Cdc6, Mcm3, and Sld2. Although we do not yet have evidence that Mck1 targets these proteins, it would be interesting to study whether Mck1 targets other proteins besides Cdc6p.

The *Δmck1* cells are not sensitive to MMS ([Figure 5E](#F5){ref-type="fig"}), which suggests that the DNA damage checkpoint might be activated and protects *Δmck1* cells even after the accumulation of DNA damage. Deletion of a DNA damage checkpoint gene enhanced *Δmck1* sensitivity to MMS, supporting the hypothesis ([Figure 5E](#F5){ref-type="fig"}). [@B10] reported that overexpression of *MCK1* suppresses lethality in *rad53* mutants, indicating that Mck1p has a role in DNA damage repair. We propose a model in which Cdc6 inhibition by Mck1 under DNA damage stress ensures genome integrity and maintenance of proper cell proliferation. We also observed that overexpression of *CDC6* but not the *CDC6-T368A* mutant partially rescues MMS sensitivity in the *mre11*-deletion strain ([Figure 5E](#F5){ref-type="fig"}, bottom). Mcm complex plays a role in the DNA damage--induced signaling that controls DNA replication ([@B8]). Overexpression of Cdc6 helps Mcm complex to be loaded on DNA ([@B17]), which may enhance the DNA damage signaling pathway to rescue the *Δmre11* lethality to MMS.

In humans, deregulation of replication factors, such as Cdc6, has been observed in many cancers. For instance, Cdc6 overexpression has been associated with brain tumors ([@B42]), cervical cancer ([@B37]), and lung carcinomas ([@B23]). Given the implication of Cdc6 up-regulation in human cancers ([@B4]), it would be of considerable interest to study whether mammalian GSK-3 kinase plays a role in Cdc6 degradation. Cdc6 degradation during alkylating DNA damage is conserved between humans and yeasts ([@B18]). Therefore it is possible that human GSK-3 kinase, similar to Mck1, might promote Cdc6 degradation. A link between mammalian GSK-3 kinase and the DNA damage response has been reported. GSK-3 kinase phosphorylates the oncogenic metazoan transcription factor c-Myc after DNA damage triggered by ultraviolet light. The phosphorylated c-Myc is targeted for ubiquitination by SCF^Fbw7^, the human homologue of Cdc4 ([@B45]). Of interest, c-Myc was shown to have a nontranscriptional role in the initiation of DNA replication ([@B11]). Although it is not clear whether the c-Myc degradation during DNA damage is associated with the replication function of c-Myc, it would support the general idea that DNA replication is inhibited during DNA damage through degradation of replication proteins.

MATERIALS AND METHODS
=====================

Plasmids and strains
--------------------

Standard methods were used for mating, tetrad dissection, and transformation. All strains listed in Supplemental Table S1 are congenic with W303. p305-based *GAL-CDC6-HA* plasmid was a gift from Stephen P. Bell (Massachusetts Institute of Technology, Cambridge, MA). *GAL-CDC6-HA* strains were made as described previously ([@B54]). Briefly, *GAL-CDC6-HA* plasmid was linearized with *Stu*I and integrated at the *URA* locus in the wild-type strain. The copy number of the integrated *GAL-CDC6* was determined by real-time PCR. *GAL-CDC6* mutations were made by site-directed mutagenesis (QuikChange II XL mutagenesis kit; Agilent, Santa Clara, CA) using the *GAL-CDC6-HA* plasmid as a template. The mutagenized *GAL-CDC6* plasmid was integrated at the *URA* locus in wild-type cells, and the copy number was determined as described. *MCK1-9MYC* strain was constructed as described previously ([@B26]). *CDC6-T368A* and *CDC6-T39A,T368A* strains were generated by two-step PCR in order to integrate the mutation into the genomic locus ([Figures 4C](#F4){ref-type="fig"} and [5F](#F5){ref-type="fig"}; [@B53]).

Cell cycle block experiments
----------------------------

Mitotic cell cycle arrest was achieved using 15 μg/ml nocodazole for 2 h at 30°C. *GAL-CDC6--HA* strains were grown to log phase in medium containing 3% raffinose. Galactose was then added to induce *CDC6-HA* expression for 2 h, followed by incubation in nocodazole for another 2 h. Glucose was then added to shut off the expression. For the α-factor arrest experiments, log-phase cells were arrested in G1 using 100 nM α-factor for 2 h at 30°C.

Western blotting
----------------

Cells were lysed by agitation in SDS sample buffer with glass beads using FastPrep (MP Biomedicals, Santa Ana, CA) for 20 s, twice, at speed 6. Proteins were separated by SDS--PAGE with 10% polyacrylamide gel, except for the samples in [Figure 2](#F2){ref-type="fig"}, which were separated using SDS--PAGE with Novex 4--20% Tris-glycine polyacrylamide gel (Invitrogen, Life Technologies, Carlsbad, CA). Western blot analysis was performed using anti-hemagglutinin (HA) antibody 3F10 (Roche, Penzberg, Germany) at 1:2000 dilution, anti-Clb2 antibody (a generous gift from Frederick Cross, Rockefeller University, New York, NY), anti--phospho Cdc6-T368 antibody at 1:1000 dilution (custom-made antibody by 21st Century Bio, Marlboro, MA), anti-cMYC antibody 9E10 (Sigma-Aldrich, St. Louis, MO) at 1:2000 dilution, and anti-Pgk1 (Life Technologies, Carlsbad, CA) at 1:2000 as a loading control. Protein A--tagged proteins were probed using horseradish peroxidase--conjugated anti-rabbit immunoglobulin G (Sigma-Aldrich) at 1:5000.

To detect phospho--Cdc6-T368, *CDC6* was immunoprecipitated by HA-affinity purification first in order to enhance the signal ([@B22]).

Kinase assay
------------

Clb2-Cdk1 and Mck1 proteins were purified from yeast cells expressing TAP-tagged proteins as previously described ([@B34]). The TAP-tagged plasmid for Clb2 and Mck1 were kindly provided by David O Morgan (University of California, San Francisco, San Francisco, CA; [@B33]). Peptide kinase assay was performed as described ([@B33]) at room temperature for 30 min using purified Mck1 or Clb2-Cdk1 with 5 μM peptides (synthesized by NeoBioLab, Woburn, MA) in a 15-μl total reaction, with 0.6 μCi of \[γ-^32^P\]ATP (3000 μCi mmol^−1^; PerkinElmer, Melville, NY). After stopping the reaction and washing, radioactivity was measured using a scintillation counter (Tri-Carb 2800; PerkinElmer; [@B46]).

Microscope
----------

Cells were grown in low-fluorescence medium, which was prepared as described previously ([@B49]). Cells were imaged on an Eclipse 90i microscope (Nikon, Tokyo, Japan) with a total internal reflection fluorescence 60×/1.45 numerical aperture Plan Apochromatic objective lens (Nikon) fitted with a cooled Clara interline charge-coupled device camera (Andor, Belfast, United Kingdom) and using an Intensilight Ultra High Pressure 130-W mercury lamp (Nikon) as an illumination source. Images were acquired using the NIS Element BR software (Nikon). Image acquisition times for green fluorescent protein, YFP, 4′,6-diamidino-2-phenylindole (DAPI), and differential interference contrast (DIC) were 300, 200, 50, and 50 ms, respectively. All images were processed using ImageJ software (National Institutes of Health, Bethesda, MD; [@B48]). To visualize *RAD52-YFP* foci, the DIC image was acquired, followed by seven YFP images at 0.5-μm intervals along the *z*-axis. YFP image stacks were combined through maximum intensity projection in order to count Rad52-YFP foci along the entire *z*-stack for each field. The corresponding DIC images were used as a reference to determine the budding of the cells. Log-phase *MCK1-GFP* cells were lightly fixed in 4% paraformaldehyde and then stained with DAPI. The fixed cells were imaged using the relevant wavelengths, and the images were pseudocolored and processed using ImageJ.

Yeast two-hybrid assay
----------------------

The pBTM116 constructs containing Cdc6 is a generous gift from J. Diffley\'s lab (Francis Crick Institute, London, UK; [@B43]). The CDC6-pBTM116 plasmid was subjected to site-directed mutagenesis to create the various Cdc6 mutants (QuikChange Lightning Kit; Agilent). The *CDC4*/pACT plasmid and each of the various *CDC6*/pBMT116 plasmids were cotransformed into L40 strain and plated on synthetic defined-Leu/Trp plates, and β-galactosidase activity was measured as described previously ([@B22]).
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MMS

:   methyl methanesulfonate.
